Macular Degeneration Treatment Market Report 2025

The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $11.05 billion in 2024 to $12.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to aging population, lifestyle changes, limited treatment options, rising awareness, healthcare infrastructure development.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $19.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, global efforts for vision health. Major trends in the forecast period include focus on neuroprotection and regeneration therapies, expansion of telemedicine and remote monitoring, personalized medicine approaches, investigation of stem cell therapies, patient-focused initiatives for awareness and education.

The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.

The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.

Major companies in the macular degeneration treatment market are concentrating on the development of biosimilars for age-related macular degeneration (AMD) to enhance access to effective therapies. Biosimilars are biological medical products that are highly comparable to an already approved reference product, demonstrating no clinically meaningful differences in safety, purity, or potency. For example, in May 2024, Biocon Biologics Ltd, based in India, and Samsung Bioepis Co. Ltd, a South Korean company, received FDA approval for their two new biosimilars, Yesafili and Opuviz. Both biosimilars target vascular endothelial growth factor (VEGF), which is implicated in abnormal blood vessel growth in the eye, thus helping to prevent vision loss related to AMD and diabetic retinopathy. The FDA's approval process included comparative studies demonstrating that Yesafili and Opuviz have no significant differences in efficacy or safety compared to Eylea. These studies involved comprehensive assessments of the biosimilars' pharmacokinetics and immunogenicity.

Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.

In July 2023, Harrow Inc., a US-based company, acquired Santen for $8 million. This acquisition is part of Harrow's strategy to enhance its portfolio by leveraging Santen's expertise in macular degeneration treatment. Santen Pharmaceutical Co., Ltd. is a Japan-based company specializing in treatments for macular degeneration.

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macula is the central part of the retina responsible for central vision. Age-related macular degeneration (AMD) is a common condition in individuals over 60, resulting in the degeneration of the macula and causing distortion or loss of central vision. Treatment aims to slow the progression of the disease and prevent severe vision loss.

The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

The macular degeneration treatment research report is one of a series of new reports that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.